Sofia Genta1, Maria Cristina Pirosa1, Anastasios Stathis2. 1. Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500, Bellinzona, Switzerland. 2. Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500, Bellinzona, Switzerland. anastasios.stathis@eoc.ch.
Abstract
PURPOSE OF REVIEW: Increasing evidence suggests that epigenome plays a central role in cancer development making it a promising target for anticancer treatments. Here, we review two new classes of epigenome-targeting agents: the bromodomain and extraterminal domain proteins (BET) inhibitors and the enhancer of zeste homolog (EZH2) inhibitors. RECENT FINDINGS: Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors. Several studies on BETi and EZH2i are ongoing to better define their potential role in cancer treatment, which patients are most likely to benefit and if the association with other drugs can improve their efficacy.
PURPOSE OF REVIEW: Increasing evidence suggests that epigenome plays a central role in cancer development making it a promising target for anticancer treatments. Here, we review two new classes of epigenome-targeting agents: the bromodomain and extraterminal domain proteins (BET) inhibitors and the enhancer of zeste homolog (EZH2) inhibitors. RECENT FINDINGS: Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors. Several studies on BETi and EZH2i are ongoing to better define their potential role in cancer treatment, which patients are most likely to benefit and if the association with other drugs can improve their efficacy.
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan Journal: Nature Date: 2014-04-23 Impact factor: 49.962
Authors: Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: I-Hsin Su; Ashwin Basavaraj; Andrew N Krutchinsky; Oliver Hobert; Axel Ullrich; Brian T Chait; Alexander Tarakhovsky Journal: Nat Immunol Date: 2002-12-23 Impact factor: 25.606
Authors: Adrian P Bracken; Diego Pasini; Maria Capra; Elena Prosperini; Elena Colli; Kristian Helin Journal: EMBO J Date: 2003-10-15 Impact factor: 11.598
Authors: Panagiotis Ntziachristos; Aristotelis Tsirigos; Pieter Van Vlierberghe; Jelena Nedjic; Thomas Trimarchi; Maria Sol Flaherty; Dolors Ferres-Marco; Vanina da Ros; Zuojian Tang; Jasmin Siegle; Patrik Asp; Michael Hadler; Isaura Rigo; Kim De Keersmaecker; Jay Patel; Tien Huynh; Filippo Utro; Sandrine Poglio; Jeremy B Samon; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Raul Rabadan; Ross L Levine; Stuart Brown; Francoise Pflumio; Maria Dominguez; Adolfo Ferrando; Iannis Aifantis Journal: Nat Med Date: 2012-02-06 Impact factor: 53.440
Authors: Frances Potjewyd; Anne-Marie W Turner; Joshua Beri; Justin M Rectenwald; Jacqueline L Norris-Drouin; Stephanie H Cholensky; David M Margolis; Kenneth H Pearce; Laura E Herring; Lindsey I James Journal: Cell Chem Biol Date: 2019-12-09 Impact factor: 8.116
Authors: Leticia Serrano-Oviedo; Miriam Nuncia-Cantarero; Sara Morcillo-Garcia; Cristina Nieto-Jimenez; Miguel Burgos; Veronica Corrales-Sanchez; Javier Perez-Peña; Balázs Győrffy; Alberto Ocaña; Eva María Galán-Moya Journal: Cell Oncol (Dordr) Date: 2020-03-12 Impact factor: 6.730
Authors: P Khoueiry; A Ward Gahlawat; M Petretich; A M Michon; D Simola; E Lam; E E Furlong; V Benes; M A Dawson; R K Prinjha; G Drewes; P Grandi Journal: Epigenetics Chromatin Date: 2019-07-02 Impact factor: 4.954
Authors: Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin Journal: Nat Rev Clin Oncol Date: 2019-09-23 Impact factor: 66.675